Terms: = Breast cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Clinical Outcome
11 results:
1. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract] [Full Text] [Related]
2. Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression.
Giannoudis A; Varešlija D; Sharma V; Zakaria R; Platt-Higgins A; Rudland PS; Jenkinson MD; Young LS; Palmieri C
ESMO Open; 2022 Dec; 7(6):100636. PubMed ID: 36423363
[TBL] [Abstract] [Full Text] [Related]
3. MUC1 triggers lineage plasticity of Her2 positive mammary tumors.
Pang Z; Dong X; Deng H; Wang C; Liao X; Liao C; Liao Y; Tian W; Cheng J; Chen G; Yi H; Huang L
Oncogene; 2022 May; 41(22):3064-3078. PubMed ID: 35461328
[TBL] [Abstract] [Full Text] [Related]
4. CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma.
Lai C; Coltart G; Shapanis A; Healy C; Alabdulkareem A; Selvendran S; Theaker J; Sommerlad M; Rose-Zerilli M; Al-Shamkhani A; Healy E
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479027
[TBL] [Abstract] [Full Text] [Related]
5. Tumor membrane-based vaccine immunotherapy in combination with anti-ctla-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer.
Pack CD; Bommireddy R; Munoz LE; Patel JM; Bozeman EN; Dey P; Radhakrishnan V; Vartabedian VF; Venkat K; Ramachandiran S; Reddy SJC; Selvaraj P
Hum Vaccin Immunother; 2020 Dec; 16(12):3184-3193. PubMed ID: 32530786
[TBL] [Abstract] [Full Text] [Related]
6. Molecular stratification within triple-negative breast cancer subtypes.
Wang DY; Jiang Z; Ben-David Y; Woodgett JR; Zacksenhaus E
Sci Rep; 2019 Dec; 9(1):19107. PubMed ID: 31836816
[TBL] [Abstract] [Full Text] [Related]
7. Functional heterogeneity of circulating T regulatory cell subsets in breast cancer patients.
Ostapchuk YO; Perfilyeva YV; Kustova EA; Urazalieva NT; Omarbaeva NA; Talaeva SG; Belyaev NN
Breast Cancer; 2018 Nov; 25(6):687-697. PubMed ID: 29797233
[TBL] [Abstract] [Full Text] [Related]
8. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (ctla-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract] [Full Text] [Related]
9. Relationship of P-cadherin expression to basal phenotype of breast carcinoma.
Potemski P; Kusińska R; Kubiak R; Piekarski JH; Płuciennik E; Bednarek AK; Kordek R
Pol J Pathol; 2007; 58(3):183-8. PubMed ID: 18074863
[TBL] [Abstract] [Full Text] [Related]
10. Cardiac dysfunction in the trastuzumab clinical trials experience.
Seidman A; Hudis C; Pierri MK; Shak S; Paton V; Ashby M; Murphy M; Stewart SJ; Keefe D
J Clin Oncol; 2002 Mar; 20(5):1215-21. PubMed ID: 11870163
[TBL] [Abstract] [Full Text] [Related]
11. Upstream stimulatory factors mediate estrogen receptor activation of the cathepsin D promoter.
Xing W; Archer TK
Mol Endocrinol; 1998 Sep; 12(9):1310-21. PubMed ID: 9731700
[TBL] [Abstract] [Full Text] [Related]
